Cell Therapy Next Current Issue

The following articles appeared in the print edition of Cell Therapy Next.

Table of Contents

• Getting to the heart of CAR T-cell therapy’s cardiovascular risks Drew Amorosi
• Trial of Kymriah for advanced follicular lymphoma meets primary efficacy endpoint
• Bristol-Myers Squibb, bluebird bio resubmit application for CAR-T to treat advanced myeloma
• FDA clears IND application for cell therapy to treat HIV
• FDA clears IND for first CAR macrophage cell therapy for HER2-positive tumors
• FDA grants fast track designation to allogeneic CAR T-cell therapy for advanced ALL
• FDA panel supports Ryoncil cell therapy for children with acute GVHD
• FDA places clinical hold on trial for off-the-shelf CAR-T for advanced myeloma
• FDA approval of CAR-T for mantle cell lymphoma could be ‘practice changing’ Drew Amorosi
• NCCN patient guidelines provide ‘basic understanding’ of CAR T-cell therapy toxicities Drew Amorosi
• Regulatory T-cell therapy shows promise for COVID-19-related respiratory distress Drew Amorosi
• Limiting severe toxicity, mortality after CAR T-cell therapy Drew Amorosi
• Post-infusion CAR-T costs considerably higher at academic inpatient hospitals Drew Amorosi
• Researchers develop tool to predict CAR T-cell therapy-associated neurotoxicity Drew Amorosi
• PD-1-armored CAR T cells appear safe, effective for advanced non-Hodgkin lymphoma Drew Amorosi
• T-cell therapy trial fails to meet primary efficacy endpoint for refractory NSCLC Drew Amorosi